Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 3/20 | 0.31 |
| ▸ | MMP9 | P14780 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975609 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2962529 | 0.81 | KDM1A (0.37) | EGFRERBB2KDM1ACYP1A2ALDH1A1 | |
| SCHEMBL2974786 | 0.81 | TRPM2 (0.35) | EGFRERBB2CYP2A6KDM1ACYP1A2 | |
| SCHEMBL2967545 | 0.81 | HTR2C (0.33) | — | |
| SCHEMBL2959653 | 0.80 | EGFR (0.33) | EGFRERBB2CYP2A6KDM1ACYP1A2 | |
| SCHEMBL2959777 | 0.80 | KDM1A (0.33) | CYP2A6KDM1ACYP1A2ALDH1A1SLC6A4 | |
| SCHEMBL2967939 | 0.77 | MAOB (0.33) | MAOB | |
| SCHEMBL2960040 | 0.77 | CYP2A6 (0.36) | CYP2A6KDM1ACYP1A2ALDH1A1SLC6A4 | |
| SCHEMBL2968703 | 0.77 | CYP2A6 (0.36) | CYP2A6KDM1ACYP1A2ALDH1A1SLC6A4 | |
| SCHEMBL2964528 | 0.77 | KDM4E (0.38) | EGFRERBB2CYP2A6SLC6A4MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | EGFR 132/4885ERBB2 168/4885CYP2A6 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.